Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland

Guideline from the Working Party Hemostasis of the Swiss Society of Hematology

Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana, on behalf of the Working Party of Hemostasis (WPH) of the Swiss Society of Hematology (SGH-SSH)

Summary
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but not eliminated. Major bleeding events related to the use of factor Xa inhibitors can be challenging to manage. In recent years, four-factor prothrombin complex concentrates have been used in patients with severe bleeding taking oral direct factor Xa inhibitors (apixaban, edoxaban and rivaroxaban). Andexanet alfa (Ondexxya™, AstraZeneca AG) is a specially designed recombinant version of human factor Xa that acts as a decoy receptor to reverse the effects of factor Xa inhibitors. Since 2 December 2020, andexanet alfa has been used in Switzerland for adult patients receiving apixaban or rivaroxaban when reversal of anticoagulation is required because of life-threatening or uncontrolled bleeding. However, the use of andexanet alfa remains a challenge owing to its cost, the reported thromboic complications and the fact that its efficacy mainly relates to intracranial haemorrhage. Moreover, the use of nonspecific reversal agents together with andexanet alfa is controversial. The present recommendations on the use of andexanet alfa in the management of bleeding in patients on factor Xa inhibitors in Switzerland were developed by a group of Swiss experts from the Working Party Hemostasis of the Swiss Society of Hematology. These recommendations aim to provide support to clinicians in their decision-making in the management of patients with major bleeding receiving factor Xa inhibitors.

Introduction
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. The risk of major bleeding has been reduced by half with direct oral anticoagulants (DOACs) since their introduction compared with that with vitamin K antagonists. This means that, for example, the annual rate of major bleeding and intracranial haemorrhage is still 2–3% and 0.3–0.5% in patients with atrial fibrillation receiving DOACs, respectively [1].

Among DOACs, oral direct factor Xa inhibitors [apixaban (Eliquis®), edoxaban (Lixiana®) and rivaroxaban (Xarelto®)] are increasingly becoming commonly used for oral anticoagulation [2]. They have a rapid onset of action and significant anticoagulant activity. This activity can be expected as early as within the first 4 hours of administration and may last up to 48 hours or more in some patients (e.g. patients with impaired renal function) [3, 4]. Importantly, the in-hospital mortality rate is nearly 30% in patients with spontaneous intracranial haemorrhage receiving factor Xa inhibitors, with a higher risk of mortality in patients on factor Xa inhibitors than in those without anticoagulation [5].

Acute major bleeding events associated with the use of factor Xa inhibitors may be challenging to manage. Four-factor prothrombin complex concentrates (4F-PCCs; e.g. Beriplex®, Octaplex® and Prothromplex®) are plasma-derived concentrates that contain factors II, VII, IX and X. The haemostatic efficacy of 4F-PCCs has been studied in two prospective cohorts; these drugs yielded good effects in 69% and 65% of patients, respectively [7, 8]. Andexanet alfa (Ondexxya™, AstraZeneca AG) is a specially designed recombinant version of human factor Xa that acts as a decoy receptor to reverse the effects of factor Xa inhibitors in cases of bleeding [9]. It was registered for use in Switzerland on 2 December 2020 [10, 11]. Current evidence is based on an open-label, single-arm, observational phase IIIb/IV study (ANNEXA-4 study) that enrolled 479 patients with major bleeding (69% of them had intracranial haemorrhage) and prior use of a factor Xa inhibitor (apixaban, rivaroxaban, edoxaban or enoxaparin) [12, 13]. Notably, the efficacy of andexanet alfa was evaluated in patients with baseline anti-Xa activity of at least 75 ng/
ml, and around 95% of the population had an anti-Xa activity above 100 ng/ml [12, 13]. The ANNEXA-4 study showed a clinically good to excellent haemostasis with the infusion of andexanet alfa in 80% of cases of haemorrhage and a reduction in anti-Xa activity of more than 90% during infusion in the DOAC-treated groups and 75% in the enoxaparin-treated group. However, in the ANNEXA-4 study, andexanet alfa-mediated decrease in anti-Xa activity seemed to be modestly predictive of a better haemostatic efficacy only in patients with intracranial haemorrhage [12, 13]. The post-hoc ANNEXA-4 sub-study focused on haemostatic efficacy and anti-factor Xa reversal in patients with intracranial haemorrhage and showed that andexanet alfa improved haemostasis and reduced anti-factor Xa activity [14]. In an indirect comparative study employing ANNEXA-4 study data and a synthetic control arm of 4F-PCC-treated patients with intracranial haemorrhage, andexanet alfa was associated with a greater likelihood of achieving effective haemostasis (86% versus 68%, odds ratio = 2.7, confidence interval = 1.2–6.4) [15]. In a retrospective study analyzing the use of the health-system guideline, a comparable haemostatic efficacy was observed in patients receiving andexanet alfa and 4F-PCC, and a greater incidence of thromboembolic events was noted in patients receiving andexanet alfa than in those receiving 4F-PCC [16]. Another small retrospective study showed a comparable haemostatic efficacy and no difference in thromboembolic events between andexanet alfa and 4F-PCC in patients with intracranial haemorrhage [17]. In another study, andexanet alfa was associated with a lower rate of haematoma expansion in patients with atraumatic factor Xa inhibitor-related intracranial haemorrhage, but without translating into significantly improved clinical outcomes [18]. Finally, a recent meta-analysis showed a similar efficacy between 4F-PCC and andexanet alfa in patients with life-threatening bleeding, with a particularly high thrombotic rate with andexanet alfa [19]. Indeed, in the ANNEXA-4 study, 10% of patients had a thromboembolic complication, and 16% died [13]. Therefore, the mortality rate among the patients in the ANNEXA-4 trial is lower than that among some cohorts of patients with factor Xa inhibitor-associated major bleeding [7, 8, 20, 21].

Taken together, the available data point to a clinical benefit of andexanet alfa that might be restricted to patients with intracranial haemorrhage and raise concerns about thromboembolic events. It is worth noting that from June 2023, the ANNEXA-4 trial (NCT03661528), a post-marketing phase IV trial comparing the efficacy and safety of andexanet alfa in patients on oral FXa inhibitor therapy, including apixaban and rivaroxaban, with acute intracranial haemorrhage, versus usual care (including 4F-PCC), has been stopped after the interim analysis of the first 450 patients [67]. The decision was based on fulfillment of pre-specified stopping criteria of superior haemostatic efficacy, the ability to limit the expansion of life-threatening bleeding in the brain, compared with usual care. The final data are currently being analysed and publication is still expected in 2023.

Along with clinical study data, it must be recognized that compared with andexanet alfa, 4F-PCC provides a major cost advantage in Switzerland. At the time of manuscript submission, the ex-factory price for andexanet alfa (“Preisliste” from AstraZeneca, January 2023) is 49,881 CHF for the low dose and 89,785.80 CHF for the high dose. Conversely, the compendium prices for 4F-PCC (5,000 U, high dosing based on 100-kg weight) are 3,058 CHF for Beriplex®, 3,181 CHF for Octaplex® and 3,330 CHF for Prothromplex® [10]. Moreover, the cost of andexanet alfa is currently not reimbursed by health insurance companies or through Swiss Diagnosis Related Groups with supplement billing.

Most guidelines (table 1) advise the use of specific antidotes, when available, to reverse the effects of DOACs. If specific reversal agents are not available, guidelines suggest using nonspecific agents instead, including 4F-PCCs. However, for patients with major bleeding during DOAC therapy for venous thromboembolism, the 2018 ASH guidelines recommend the use of either andexanet alfa or 4F-PCCs in addition to holding DOACs or holding DOACs alone. No recommendation is made regarding the use of one agent over the other owing to the lack of comparative studies. Finally, for patients who require long-term or indefinite anticoagulation and who survive major bleeding, the 2018 ASH guidelines suggest resuming DOACs within 90 days rather than discontinuing them indefinitely [22]. In line with this recommendation, it is essential to assess patients’ indication for anticoagulation and the underlying thrombotic risk to anticipate the timing and dose of thromboprophylaxis as well as full anticoagulation resumption following anticoagulation reversal.

Antithrombotic therapy can be reinstated as soon as medically indicated, after treatment of the bleeding episode and removal of its cause, if patients’ clinical condition is stable and if proper haemostasis has been achieved. Although in cases of major bleeding, additional measures aside from supportive management might be required and include possible combination of specific and nonspecific reversal agents, the current guidelines do not provide recommendations regarding these combinations. Notably, however, the peri-/intraoperative use of andexanet alfa is off-label.

The Working Party of Hemostasis (WPH) of the Swiss Society of Hematology (SGH-SSH) offers a guideline for the utilization of andexanet alfa in the management of bleeding in patients on factor Xa inhibitors based on current available evidence, international guidelines and consensus opinions of experts. The paper integrates reversal anticoagulation with factor Xa inhibitors in the management of life-threatening or uncontrolled bleeding, including intracranial haemorrhage, allowing direct implementation. In addition, the Working Party of Hemostasis of the Swiss Society of Hematology comments on the monitoring of the effect of andexanet alfa and the limitations created by this anticoagulation reversal approach for resumption of anticoagulation in the follow-up of a major bleeding event.

**Life-threatening bleeding as a complication of anticoagulation with DOACs**

The major complication of DOACs is serious or life-threatening bleeding, which may require rapid reversal of anticoagulation. Because DOACs have a short half-life, anticoagulation reversal is generally not necessary in patients with non-life-threatening bleeding. Equally, reversal of
DOACs is generally not warranted in patients who are not bleeding and who require non-urgent invasive procedures. However, urgent invasive procedures in non-bleeding patients on DOACs may prompt anticoagulation reversal [23, 24].

**Regulatory status**

Swissmedic [10, 11] and European Medicines Agency (EMA) [25]

Indicated for adult patients treated with a direct factor Xa inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed owing to life-threatening or uncontrolled bleeding.

Andexanet alfa is currently subject to additional monitoring to allow rapid identification of new safety information. Therefore, new suspected or serious adverse reactions must be reported.

**US Food and Drug Administration (FDA) [26]**

Indicated for patients treated with apixaban or rivaroxaban when reversal of anticoagulation is needed owing to life-threatening or uncontrolled bleeding.

<table>
<thead>
<tr>
<th>Name of the guideline</th>
<th>Apixaban/rivaroxaban</th>
<th>Edoxaban</th>
</tr>
</thead>
<tbody>
<tr>
<td>American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline 2022 [56]</td>
<td>Suggested: No routine administration of andexanet alfa or PCC for acute gastrointestinal bleeding. However, andexanet alfa could be envisaged for life-threatening gastrointestinal bleeding in hospitalized patients who have been under apixaban or rivaroxaban treatment in the last 24 hours.</td>
<td>–</td>
</tr>
<tr>
<td>American College of Cardiology 2020 [57]</td>
<td>Consider: activated charcoal</td>
<td>Consider: activated charcoal</td>
</tr>
<tr>
<td></td>
<td>1st line: andexanet alfa</td>
<td>1st line: andexanet alfa (off-label);</td>
</tr>
<tr>
<td></td>
<td>2nd line: 4F-PCC, aPCC</td>
<td>2nd line: 4F-PCC, aPCC</td>
</tr>
<tr>
<td></td>
<td>If andexanet alfa is not available: 4F-PCC</td>
<td>–</td>
</tr>
<tr>
<td>American College of Emergency Physicians 2019 [58]</td>
<td>Recommended: andexanet alfa</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Alternative: PCC</td>
<td></td>
</tr>
<tr>
<td>American Heart Association/American College of Cardiology/Heart Rhythm Society 2019 [59]</td>
<td>“Can be useful”: andexanet alfa</td>
<td>–</td>
</tr>
<tr>
<td>European Stroke Organisation 2019 [60]</td>
<td>1st line: andexanet alfa</td>
<td>1st line: PCC</td>
</tr>
<tr>
<td></td>
<td>2nd line: 4F-PCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recommended: andexanet alfa</td>
<td>Recommended: aPCC, 4F-PCC, rFVIIa, 3F-PCC</td>
</tr>
<tr>
<td></td>
<td>Alternatives: aPCC, 4F-PCC, rFVIIa, 3F-PCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>If DOAC-specific reversal agent is not available: PCC</td>
<td></td>
</tr>
<tr>
<td>American Society of Hematology 2018 [22]</td>
<td>Suggested: andexanet alfa or 4F-PCC</td>
<td>–</td>
</tr>
<tr>
<td>European Heart Rhythm Association 2018 [63]</td>
<td>Recommended: andexanet alfa</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Alternative: 4F-PCC, aPCC</td>
<td></td>
</tr>
<tr>
<td>International Society for Thrombosis and Haemostasis 2016 [64]</td>
<td>Agents under investigation: andexanet alfa, ciraparantag</td>
<td>–</td>
</tr>
<tr>
<td>Neurocritical Care Society/Society of Critical Care Medicine 2016 [65]</td>
<td>Consider: activated charcoal</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Suggested: 4F-PCC, aPCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alternative: rFVIIa</td>
<td></td>
</tr>
<tr>
<td>American Heart Association/American Stroke Association 2015 [66]</td>
<td>Consider: FEIBA, PCC, rFVIIa, activated charcoal</td>
<td>–</td>
</tr>
</tbody>
</table>

aPCC = activated prothrombin complex concentrate; DOAC = direct oral anticoagulant; 3F-PCC = three-factor prothrombin complex concentrate; 4F-PCC = four-factor prothrombin complex concentrate; FEIBA = factor VIII bypassing agent; PCC = prothrombin complex concentrate; rFVIIa = recombinant activated factor VII

**Pharmacokinetics/pharmacodynamics**

Andexanet alfa is a recombinant variant of the human factor Xa protein that is catalytically inactive owing to a mutation of the active-site S419A and a deletion of the membrane-binding gamma-carboxyglutamic acid domain. However, andexanet alfa keeps the structural similarity to endogenous factor Xa to be bound by factor Xa-inhibiting drugs, such as direct factor Xa inhibitors and antithrombin-dependent anticoagulants [9], but is unable to assemble into the prothrombinase complex and cleave prothrombin to generate thrombin. Andexanet alfa binds to apixaban, betrixaban, edoxaban and rivaroxaban with an affinity that corresponds to that of endogenous factor Xa (i.e. 0.5–1.5 nmol/l) [9]. Consequently, andexanet alfa scavenges factor Xa inhibitors, reversing the anticoagulant effects of factor Xa inhibitors and restoring the activity of endogenous factor Xa.

The distribution of andexanet alfa is 5.3 ± 2.6 L, approximately equivalent to the blood volume [10]. There are currently no data on the metabolism of andexanet alfa. Its clearance rate is 4.4 ± 1.2 L/hour with low renal elimination. The elimination half-life ranges from 4 to 7 hours [10, 25, 26]. According to knowledge of native factor Xa kinetics, andexanet alfa is likely to be rapidly degraded in the plasma by endogenous proteases, compatible with its relatively short effective half-life. Biliary and/or faecal excretion of therapeutic proteins is not a known route of protein elimination. Consequently, it is not considered necessary to...
adjust the dose in patients with hepatic insufficiency. According to available pharmacokinetic data, andexanet alfa has either limited or no renal clearance and hence would not require dose adjustment in patients with renal insufficiency [10, 11, 25, 26]. The effective half-life of andexanet alfa is 30–60 minutes [27]. Andexanet alfa is administered as a bolus followed by an infusion to sustain anticoagulation reversal until the drug is cleared from the circulation [10].

Caution
Andexanet alfa does not alter the effects of non-factor Xa-based inhibitors (e.g. dabigatran) and is currently not approved by Swissmedic, the EMA and the FDA for reversal of the anticoagulant effect of edoxaban, low-molecular-weight heparin and fondaparinux owing to the current lack of data [10, 11, 25, 26]. Nevertheless, recent publications suggest the effectiveness of andexanet alfa for edoxaban reversal as well [13, 28].

Efficacy monitoring
Monitoring of therapy should be based mainly on clinical parameters indicating adequate response (e.g. achieving haemostasis), lack of efficacy (e.g. rebleeding) and adverse events (e.g. thromboembolic episodes). Monitoring of andexanet alfa therapy should not be based on anti-factor Xa activity, as commercially available anti-factor Xa activity assays are not appropriate for measuring anti-factor Xa activity after andexanet alfa administration because they show falsely elevated levels of anti-factor Xa activity, resulting in significant underestimation of andexanet alfa reversal activity [29, 30]. This is due to the high sample dilution in the early step of commercial anti-Xa activity tests, causing the andexanet alfa–factor Xa inhibitor binding/unbinding equilibrium to shift towards the unbound state. This increases the amount of factor Xa inhibitors in the free or unbound state and thereby in the factor Xa assay. A modified commercially available anti-Xa activity test has been developed to minimize the sample dilution effect [9, 31]. This test has been used in all studies implying the use of andexanet alfa [9, 12, 31].

Issue of thrombotic events
The development of thrombotic events is a major concern for patients with anticoagulant-related bleeding who are at an increased risk not just owing to anticoagulant withdrawal and reversal but also because of haemostasis activation, invasive procedure or critical illness. However, the rate of thrombosis is comparable among patients with anticoagulant (including VKA and DOAC)-related major bleeding treated with fresh frozen plasma, 4F-PCC, idarucizumab or andexanet alfa (4–10%) [24].

Thrombotic episodes have been reported after andexanet alfa therapy [12, 19]. Patients on factor Xa inhibitors have underlying medical conditions that predispose them to thrombotic events. Factor Xa inhibitor reversal exposes these patients to the thrombotic risk of their pre-existing disease. In addition, an independent prothrombotic effect of andexanet alfa, such as tissue factor pathway inhibitor (TFPI) inhibition within 10–20 hours following andexanet alfa administration, cannot be excluded [10–12, 25, 26, 31, 32]. The duration of this effect in bleeding patients is unknown.

In healthy volunteers, dose-dependent transient increases in the coagulation markers F1+2, thrombin-antithrombin complexes and D-dimer as well as thrombin generation have been observed after andexanet alfa administration. This points to an activation of the coagulation system, which may be related to the observation of a concomitant TFPI inhibition [10–12, 25, 26, 31, 32]. Therefore, biological parameters such as anti-factor Xa activity, measurement of thrombin generation or markers of thrombosis may not be good indicators for evaluating both efficacy and thrombotic risk [30].

No thrombotic events have been reported in healthy volunteers [31]. In the ANNEXA-4 study, coagulation activation markers were not measured [12]. Monitoring for signs and symptoms of thrombosis is therefore highly advised in patients on andexanet alfa. Resumption of anticoagulant therapy should be considered as soon as possible after reversal therapy to reduce the occurrence of a thrombotic event. In addition, the relationship between laboratory markers of thrombosis and the development of clinical thrombosis is uncertain [33].

Use of andexanet alfa in combination with other supportive measures
Andexanet alfa should be used in combination with standard supportive haemostatic measures based on medical needs [10, 11, 25, 26], including endoscopy, angiography or surgery. Ultimately, definitive haemostatic intervention should be employed to stop bleeding [24].

The safety of andexanet alfa has not been evaluated in patients who have previously received 4F-PCCs, recombinant factor VIIa (rFVIIa) or blood products within 7 days prior to the bleeding event, as these patients have been excluded from clinical trials [12]. Concomitant treatment with other procoagulant factors (3F- or 4F-PCC, activated PCC or rFVIIa) should be avoided owing to the current lack of data regarding the combination of these agents [10, 11, 25, 26]. However, if clinically necessary (i.e. unresolved major bleeding), the use of these agents after the end of andexanet alfa infusion may be considered owing to the relatively short half-life [10]. Fresh frozen plasma, platelet concentrate and tranexamic acid should be used if appropriate, in line with local guidelines on massive transfusion.

Interaction with heparin
Andexanet alfa also binds to antithrombin-dependent factor Xa anticoagulants, such as unfractionated heparin, by binding to heparin-activated antithrombin [34, 35]. Consequently, andexanet alfa administration before interventions under heparin anticoagulation can promote heparin resistance or unresponsiveness, particularly in cardiovascular surgery [36–38]. Therefore, it is recommended not to use andexanet alfa prior to heparinization, especially in patients needing emergent cardiac surgery with cardiopulmonary bypass [39]. As a result of this interaction, the effect of neither heparin nor andexanet alfa can be monitored, since routine coagulation tests do not provide reliable results and cannot be used for monitoring. If patients...
are on andexanet alfa and require systemic anticoagulation for an urgent procedure, clinicians may need to consider alternative agents [26] (i.e. bivalirudin if andexanet alfa is given before cardiopulmonary bypass surgery) [39] or argatroban [37]. This topic has been approached only in case reports [36–38] and is now critically discussed in the field of cardiovascular surgery [40–42]. Therefore, prospective studies are needed before an update of actual recommendations [39].

The duration of heparin neutralization by andexanet alfa has not been studied. Further, the use of andexanet alfa as an antidote to heparin or low-molecular-weight heparin has not been evaluated and is currently not recommended.

Methodological limitations of available evidence for anticoagulant reversal with andexanet alfa and 4F-PCC

The ANNEXA-4 study lacks a comparator group. Therefore, the findings are observational, and correlations could be confounded particularly with selection bias [12, 13]. The recommendations against the use of andexanet alfa in patients with life-threatening bleeds other than intracranial haemorrhage were based on a meta-analysis [43] and small retrospective studies [16, 17, 44] because these studies did not demonstrate an advantage of prescribing andexanet alfa over 4F-PCC in this indication. Conversely, the use of 4F-PCC during bleeding in the context of anticoagulation with DOACs is based on few clinical data, and animal and in vitro or ex vivo studies as well as a lack of alternative treatment options [45–53].

Patient management

Questions to ask at admission

− Indication of anticoagulation?
− Which factor Xa inhibitor was taken?
− Dosage?
− Time of last intake?
− Other drugs with potential haemorrhagic effects?
− Complete list of medications administered to identify pharmacologic interactions that could potentiate the effects of factor Xa inhibitors. Several websites may be of help, including the following: www.compendium.ch (free to use after registration); www.swissmedicinfo.ch (free to use); www.uptodate.com/drug-interactions?source=responsive_home壮观 "di-druglist" (subscription fee needed).

Baseline laboratory analyses

− Blood cell count
− Prothrombin time, activated partial thromboplastin time and fibrinogen level
− Apixaban/rivaroxaban level (anti-Xa activity test with a dedicated calibrator), if the assay is available.
− Creatinine level
− Liver test findings (ASAT, ALAT, bilirubin, alkaline phosphatase, GGT and LDH levels)

When to administer andexanet alfa

Andexanet alfa is administered in accordance with the algorithm shown in figure 1.

Choice of dosage of andexanet alfa

The andexanet alfa dosage is determined in accordance with the data shown in table 2.

WPH/SGH-SSH recommendations (figure 1 and table 2)

− Before anticoagulation reversal is considered, it is essential to assess patients’ indication for anticoagulation with the underlying thrombotic risk to anticipate the timing and dose of thromboprophylaxis as well as full anticoagulation resumption following anticoagulation reversal. Importantly, after reversal, anticoagulation must be reinstated as soon as medically indicated, if patients’ clinical condition is stable and if proper haemostasis has been achieved.

− Andexanet alfa should be considered in patients treated with a direct factor Xa inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed owing to intracranial haemorrhage, except if the prognosis is poor regardless of haemostasis (e.g. Glasgow coma score of less than 7 or life expectancy of less than 1 month), in line with the ANNEXA-I study exclusion criteria. For all other patients with life-threatening or uncontrolled bleeding on apixaban, rivaroxaban or edoxaban, 4F-PCC (e.g. Beriplex®, Octaplex® or Prothromplex® at 25–50 U/kg IV) should be administered. The reason for the WPH/SGH-SSH recommendation to limit the use of andexanet alfa for intracranial haemorrhage is the current lack of evidence in favour of andexanet alfa administration over 4F-PCC for all other life-threatening or uncontrolled bleeding [43]. Moreover, in a retrospective analysis focusing on extracranial bleeds, a poor overall outcome, a low rate of haemostatic effectiveness and high rates of ischaemic complications and mortality following andexanet alfa anticoagulation reversion were reported [44]. An additional consideration of the Working Party Hemostasis is that the cost of andexanet alfa is currently not reimbursed by health insurance companies or through Swiss Diagnosis Related Groups with supplement billing, and andexanet alfa is significantly more expensive than 4F-PCC.

− If the anti-Xa activity is known, the administration of andexanet alfa must be restricted to patients with an anti-Xa activity above 100 ng/ml (but not to delay andexanet alfa administration upon waiting for the anti-Xa activity test result). Alternatively, andexanet alfa can be

Table 2: Modality of administration of andexanet alfa [31].

<table>
<thead>
<tr>
<th>Dose</th>
<th>Initial intravenous bolus</th>
<th>Follow-up intravenous infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low (5 vials of 200 mg)</td>
<td>400 mg at a target rate of 30 mg/minute for ~15 minutes</td>
<td>4 mg/minute over 120 minutes (480 mg)</td>
</tr>
<tr>
<td>High (9 vials of 200 mg)</td>
<td>800 mg at a target rate of 30 mg/minute for up to ~30 minutes</td>
<td>8 mg/minute over 120 minutes (960 mg)</td>
</tr>
</tbody>
</table>
administered without knowing the anti-Xa activity level if the last intake of apixaban or rivaroxaban occurred less than 15 hours ago (in line with the ANNEXA-I study).

– NB: The cut-off of the anti-Xa activity at 100 ng/ml is the cut-off selected in the ANNEXA-I study. In addition, it has been shown that below 100 ng/ml, there is no effect on red blood cell loss in a major surgery setting [54].

– Andexanet alfa is currently not recommended for reversal of edoxaban, low-molecular-weight heparin and fondaparinux owing to the current lack of data outside of the ANNEXA-4 study [12, 13]. In addition, andexanet alfa is not approved by Swissmedic for the reversal of the anticoagulation effect of these anticoagulants [10].

– 4F-PCC should be considered in patients treated with edoxaban when reversal of anticoagulation is needed owing to life-threatening or uncontrolled bleeding. Recent publications suggest the effectiveness of andexanet alfa also for edoxaban reversal [13, 28].

– Unless absolutely necessary (i.e. massive or uncontrolled haemorrhage), treatment with procoagulant factors (e.g. 3F- or 4F-PCC, activated PCC or rFVIIa) should be avoided in combination with andexanet alfa owing to the current lack of data regarding the association of these therapies with andexanet alfa [10]. Fresh frozen plasma, platelet concentrate and tranexamic acid should be used if appropriate, in line with institutional guidelines on massive transfusion.

– Monitoring of andexanet alfa therapy should be based primarily on clinical parameters indicative of an appropriate response (e.g. achievement of haemostasis), lack of efficacy (e.g. rebleeding) and adverse events (e.g. thromboembolic events).

– Monitoring of andexanet alfa therapy should not be based on anti-factor Xa activity because commercially available anti-factor Xa activity assays are not suitable for measuring anti-factor Xa activity after andexanet alfa administration.

---

**Figure 1:** Algorithm to guide andexanet alfa administration. 4F-PCC, four-factor prothrombin complex concentrate (e.g. Beriplex®, Octaplex® and Prothromplex®).

Life-threatening or uncontrolled bleeding on apixaban or rivaroxaban

Intracranial haemorrhage?

- Intracerebral or intracranial with emergent surgery/reversal of anticoagulation needed
- No
- Yes

Symptoms onset <6 hours
Glasgow Coma Score >7
Life-expectancy >1 month and
- Last intake apixaban/rivaroxaban <15 hours (if known)
- Anti-Xa >100 ng/ml (if known)
- Yes
- No

4F-PCC

Andexanet alpha

- Last dosing unknown or <8 hours
  - Apixaban <5 mg → low dose
  - Apixaban >5 mg → high dose
  - Rivaroxaban <10 mg → low dose
  - Rivaroxaban >10 mg → high dose
- Last dosing ≥8 hours
  - Low dose
Monitoring for signs and symptoms of thrombosis is strongly recommended in patients receiving andexanet alfa.

Conclusions

The WPH/SGH-SSH recommendations integrate multiple guidelines regarding the use of andexanet alfa in the management of bleeding in patients on factor Xa inhibitors. These recommendations propose that andexanet alfa is potentially suitable for the management of intracranial haemorrhage with apixaban or rivaroxaban when reversal of anticoagulation is needed. However, the WPH/SGH-SSH does not recommend the administration of andexanet alfa over 4F-PCC for other life-threatening or uncontrolled bleeding because of the current lack of evidence. Finally, the WPH/SGH-SSH provides guidance on andexanet alfa administration, highlighting indications and risks.

The WPH/SGH-SSH recommendations may be in contrast to other statements of different societies. The limitations of the WPH/SGH-SSH recommendations are inherent to the substantially low level of evidence that currently exists for most aspects of the use of andexanet alfa for reversal of anticoagulation with factor Xa inhibitors. Moreover, the cost of andexanet alfa, which is relatively high, is currently not reimbursed by health insurance companies or through Swiss Diagnosis Related Groups with supplement billing [55]. The superiority of andexanet alfa to 4F-PCC in terms of haemostasis is currently not established. Nevertheless, the interim analysis of the ANNEXA-I study showed superior haemostatic efficacy and an ability to limit the expansion of a potentially fatal cerebral haemorrhage compared with usual treatment [67]. This new information supports our current recommendation to administer andexanet alfa to patients with acute intracranial haemorrhage. Publication of the full analysis of the study is still awaited.

In conclusion, the WPH/SGH-SSH hopes that the recommendations will guide Swiss clinicians in managing patients with life-threatening or uncontrolled bleeding under anticoagulation with apixaban or rivaroxaban until more data are available.

Working Party Hemostasis of the Swiss Society of Hematology

The WPH/SGH-SSH include (alphabetical order): Lorenzo Alberio (Service and Central Laboratory of Hematology, Lausanne University Hospital, Lausanne, Switzerland), Anne Angelillo-Schererr (Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland), Lars Asmis (Center for perioperative Thrombosis and Hemostasis, Zurich, Switzerland), Eugenia Biguzzi (Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland), Alessandro Casini (Division of Angiology and Hemostasis, Geneva University Hospital, Geneva, Switzerland), Pierre Fontana (Division of Angiology and Hemostasis, Geneva University Hospital, Geneva, Switzerland), Elena Gulifetti (Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland), Bernhard Gerber (Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland), Lukas Graf (Cantonal Hospital of St Gallen, St Gallen, Switzerland), Johanna A. Kremer Hovinga (Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland), Wolfgang Korte (Cantonal Hospital of St Gallen, St Gallen, Switzerland), Maria Martinez (Division of Hematology, Basel University Hospital, Basel, Switzerland), Jan-Dirk Studt (University Clinic of Hematology, Zurich University Hospital, Zurich, Switzerland), Alice Trinchero (University Clinic of Hematology, Zurich University Hospital, Zurich, Switzerland), Walter A. Wullimann (Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne, Lucerne, Switzerland).

Potential competing interests

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflict of interest related to the content of this manuscript was disclosed.

References

Review article: Medical guidelines

Swiss Med Wkly. 2023;153:40113

Page 8 of 9